Yarbrough Capital LLC raised its holdings in Evolent Health, Inc. (NYSE:EVH – Get Rating) by 57.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 24,290 shares of the technology company’s stock after purchasing an additional 8,846 shares during the quarter. Yarbrough Capital LLC’s holdings in Evolent Health were worth $785,000 at the end of the most recent reporting period.
Other large investors have also bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in Evolent Health by 1.4% in the fourth quarter. Geode Capital Management LLC now owns 1,334,878 shares of the technology company’s stock valued at $36,936,000 after purchasing an additional 18,308 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Evolent Health by 104.9% during the 4th quarter. Principal Financial Group Inc. now owns 379,478 shares of the technology company’s stock worth $10,500,000 after acquiring an additional 194,279 shares in the last quarter. Point72 Hong Kong Ltd purchased a new stake in shares of Evolent Health during the 4th quarter worth about $72,000. Marshall Wace LLP purchased a new stake in shares of Evolent Health during the 3rd quarter worth about $1,319,000. Finally, Summit Creek Advisors LLC boosted its stake in shares of Evolent Health by 86.5% during the 4th quarter. Summit Creek Advisors LLC now owns 423,952 shares of the technology company’s stock worth $11,731,000 after acquiring an additional 196,656 shares in the last quarter. 93.27% of the stock is currently owned by institutional investors.
Several equities research analysts have recently issued reports on EVH shares. StockNews.com started coverage on shares of Evolent Health in a research note on Thursday, March 31st. They set a “hold” rating on the stock. Guggenheim started coverage on shares of Evolent Health in a research note on Tuesday, March 29th. They set a “buy” rating and a $43.00 target price on the stock. Cowen increased their target price on shares of Evolent Health from $48.00 to $50.00 and gave the stock an “outperform” rating in a research note on Tuesday. BTIG Research upped their price target on shares of Evolent Health from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, March 25th. Finally, Piper Sandler reduced their price target on shares of Evolent Health from $37.00 to $35.00 and set a “na” rating for the company in a research report on Tuesday, May 17th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $43.75.
Evolent Health (NYSE:EVH – Get Rating) last released its quarterly earnings data on Wednesday, May 4th. The technology company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.14. The company had revenue of $297.10 million during the quarter, compared to the consensus estimate of $286.81 million. Evolent Health had a negative net margin of 3.35% and a negative return on equity of 0.86%. Evolent Health’s quarterly revenue was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.06) EPS. Research analysts anticipate that Evolent Health, Inc. will post -0.03 earnings per share for the current fiscal year.
About Evolent Health (Get Rating)
Evolent Health, Inc, a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management.
- Get a free copy of the StockNews.com research report on Evolent Health (EVH)
- It’s A Comfortable Time To Buy Steelcase
- Worthington’s Posts Strong Results, But Earnings Fall On One-Off Adjustments
- A Tasty Entry Point Into Darden Restaurants International
- NXP Semiconductors: Strong Earnings & New Microcontrollers for Electric Vehicles
- Lithium Stocks Are Offering Unprecedented Opportunity To Investors
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.